Last reviewed 2026-04-23 · How we verify

OH2 injection

OH2 injection is a monoclonal antibody that targets the PD-1 receptor.

OH2 injection is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

At a glance

Mechanism of action

By binding to PD-1, OH2 injection blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and an anti-tumor immune response.

Approved indications

• Non-small cell lung cancer, PD-L1 positive
• Head and neck squamous cell carcinoma

Common side effects

• Fatigue
• Diarrhea
• Nausea
• Rash
• Pneumonitis

Key clinical trials

• OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors (PHASE1, PHASE2)
• OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer (PHASE2)
• OH2 Injection in Solid Tumors (PHASE1, PHASE2)
• OH2 Oncolytic Viral Therapy in Central Nervous System Tumors (PHASE1, PHASE2)
• OH2 Injection in Melanoma (PHASE3)
• OH2 Injection in Combination With HX008 for Melanoma. (PHASE1, PHASE2)
• OH2 Administered by Intratumoral Injection (PHASE1)
• OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• OH2 injection CI brief — competitive landscape report
• OH2 injection updates RSS · CI watch RSS
• Binhui Biopharmaceutical Co., Ltd. portfolio CI